Benutzer: Gast  Login
Titel:

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.

Dokumenttyp:
Journal Article; 2
Autor(en):
Abou-Alfa, Ghassan K; Puig, Oscar; Daniele, Bruno; Kudo, Masatoshi; Merle, Philippe; Park, Joong-Won; Ross, Paul; Peron, Jean-Marie; Ebert, Oliver; Chan, Stephen; Poon, Tung Ping; Colombo, Massimo; Okusaka, Takuji; Ryoo, Baek-Yeol; Minguez, Beatriz; Tanaka, Takayoshi; Ohtomo, Toshihiko; Ukrainskyj, Stacey; Boisserie, Frederic; Rutman, Olga; Chen, Ya-Chi; Xu, Chao; Shochat, Eliezer; Jukofsky, Lori; Reis, Bernhard; Chen, Gong; Di Laurenzio, Laura; Lee, Ray; Yen, Chia-Jui
Abstract:
Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3) that is expressed in hepatocellular carcinoma (HCC), interacts with CD16/Fc?RIIIa and triggers antibody-dependent cytotoxicity. Codrituzumab was studied vs. placebo in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy.Patients with advanced HCC who had failed prior systemic therapy, ?18years, Eastern cooperative oncology group (ECOG) 0-1, Child-Pugh A were randomized 2:1 to biweekly c...     »
Zeitschriftentitel:
J Hepatol
Jahr:
2016
Band / Volume:
65
Heft / Issue:
2
Seitenangaben Beitrag:
289-95
Sprache:
eng
Volltext / DOI:
doi:10.1016/j.jhep.2016.04.004
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/27085251
Print-ISSN:
0168-8278
TUM Einrichtung:
II. Medizinische Klinik und Poliklinik (Gastroenterologie)
 BibTeX